Baudax Bio Inc · OTC:BXRXQ
Baudax Bio — Investor Presentation (October 2023)
17 slides from Baudax Bio's investor presentation, October 2023
Slide 1: October 2023
October 2023 3Teralmmune BaUDax BIO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opport
Slide 3: Highlights
Highlights Powerful Combined Team Baudax Bio: Development and Commercialization Teraimmune: Discovery Platform and Research • IND cleared for TCR Treg, expected “once and done” treatment to eradicate “inhibitors/auto-antibodies” interfering with Factor VIII therapy for Hemophilia A. • Q1 ‘24 target
Slide 4: Senior Leadership Team
Senior Leadership Team Gerri Henwood - President & CEO Stewart Mc Callum, MD - Consulting CMO Founder, President, CEO Baudax, Recro EVP Medical Affairs, Baudax, Recro President of Malvern Consulting Group Medical Director, GSK Founder, Pres., CEO Auxilium (NASDAQ: AUXL) Assistant Professor of Urolog
Slide 5: What is the opportunity?
What is the opportunity? Commercial opportunity could produce peak year sales of $50-100 Million, assuming TPP met. • Expected Q1 ‘24 open and begin enrollment of Phase 1/2a TI 168 trial in Hemophilia A patients with inhibitors. • Clinical trial for an orphan drug complication. Treatment expected to
Slide 6: Hemophilia A with Inhibitors
Hemophilia A with Inhibitors • Estimated 180,000 Hemophilia A patients in the developed world • Hemophilia A patients do not make Factor VIII, needed for normal blood clotting • About 30% of the Hemophilia A patients develop antibodies to Factor VIII, called inhibitors that make it hard to use Facto
Slide 7: Proprietary First-In-Class Platform for Manufacturing TCR Tregs
Proprietary First-In-Class Platform for Manufacturing TCR Tregs Immune cell collection Treg isolation 1 2 Viral TCR transduction 3 Receptor Engineering Infusion 6 Ex vivo Expansion 4 Freezing/ 5 Packaging • culture reagents • cytokines • Treg stabilizer • Plus Proprietary Technology • These unique T
Slide 8: TCR Treg Mechanism of Action in Autoimmune Disease
TCR Treg Mechanism of Action in Autoimmune Disease Antigen recognition induces expression of effector T cells, activating B cells Autoimmune Disease B cells proliferate and differentiate into autoantibody- secreting cells TCR Tregs block Treatment with pathologic Autoantigen- TCR Tregs specific B ce
Slide 9: FVIII TCR-Tregs Suppress anti-FVIII Antibody Formation in HA Mice
FVIII TCR-Tregs Suppress anti-FVIII Antibody Formation in HA* Mice Non-specific TCR Tregs Non-specific TCR Tregs FVIII TCR Tregs FVIII TCR Tregs Non FVIII CAR Tregs FVI FVIII CAR Tregs FVI Study protocol Time course of anti-FVIII antibody response • Hemophilic mice were subcutaneously • FVIII Engine
Slide 10: TCR Treg Program
TCR Treg Program NEXT STEPS: Initiate TI-168 Clinical Program for treatment of Hemophilia A inhibitors • TI-168 IND with associated preclinical and manufacturing data as well as clinical study protocol have been cleared. • Initiating clinical study process • Study site selection (specially qualified
Slide 11: Research Program Priorities
Research Program Priorities Multiple Sclerosis (MS) TCR Treg research to target CNS auto-immunity • Preclinical model development and qualification is completed • CMC and preclinical model studies preparatory work for IND • IND filing target : 2025 Myasthenia Gravis (MG) TCR Treg research to target
Slide 12: Strong Interest in Treg Cell Therapies Companies
Strong Interest in Treg Cell Therapies Companies $95M on Series A $157M on Series A $85M on Series A Preclinical MS, TTD Preclinical T1D Preclinical Autoimmune Acquired by Merck $85M up front for $1.85B Phase I $2B in development & Ulcerative Colitis commercial milestones 2021 2022 2023 $84M on Seri
Slide 13: NMB Portfolio
NMB Portfolio
Slide 14: NMB – Anesthesia Pipeline
NMB – Anesthesia Pipeline Continue at modest, sustainable pace Pre-clinical Phase 1 Phase 2 Phase 3 Milestones NEUROMUSCULAR BLOCKING AGENTS (NMBs) IV Intermediate-action (BX1000) Top-line data reported/Q2 2023 IV Ultra-short action (BX2000) Last patient dosed/end ‘24 NMB REVERSAL (ANESTHESIA) IND a
Slide 15: Baudax Bio Recent Financing
Baudax Bio Recent Financing $1.9 Million $4 Raised in August 2023 Million through additional $4.3 financing $5 Million Million Gross Proceeds from May 2023 Public Offering Raised in early January 2023 Gross Proceeds from December through warrant exercise 2022 Public Offering 15
Slide 16: Highlights
Highlights Powerful Combined Team Baudax Bio: Development and Commercialization Teraimmune: Discovery Platform and Research • IND cleared for TCR Treg, expected “once and done” treatment to eradicate “inhibitors/auto-antibodies” interfering with Factor VIII therapy for Hemophilia A. • Q1 ‘24 target
Slide 17: Contact Information
Mike Moyer Contact Information LifeSci Advisors mmoyer@lifesciadvisors.com